News & Updates

A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).

Urea is as effective as tolvaptan in the treatment of hyponatremia, with a lower incidence of overcorrection, as shown in a study.